Cadrenal Therapeutics, Inc. (CVKD) earnings
CVKD earnings moved a median of +1.13% by the close. Quarterly and annual CVKD reports and results, each read against the price at its own news timestamp. Back to the CVKD overview →
22 measured CVKD earnings events.
Where these CVKD earnings landedvs 22 measured CVKD earnings reactions
| Middle 50% of CVKD earnings reactions | -0.44% to +6.23% |
|---|---|
| Median reaction (to close) | +1.13% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 CVKD earnings events with a measured close landed between -0.44% and +6.23%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process | Press release | +0.00% | -0.53% | |
| Form 10-Q Cadrenal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -0.53% | |
| Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA | Press release | +1.53% | -2.75% | |
| Form 10-Q Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.53% | -2.75% | |
| Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting | Press release | +3.00% | +18.25% | |
| Form 10-K Cadrenal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +3.00% | +18.25% | |
| Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +3.82% | +2.17% | |
| Form 10-Q Cadrenal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.82% | +2.17% | |
| Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -0.18% | |
| Form 10-Q Cadrenal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -0.18% | |
| Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -6.06% | |
| Form 10-Q Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -6.06% | |
| Form 10-K Cadrenal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.41% | +7.67% | |
| Form 10-Q Cadrenal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.37% | +7.58% | |
| Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update | Press release | — | +11.05% | |
| Form 10-Q Cadrenal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | +11.05% | |
| Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update | Press release | +2.21% | +1.13% | |
| Form 10-Q Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.21% | +1.13% | |
| Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update | Press release | +4.30% | +1.37% | |
| Form 10-K Cadrenal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +4.30% | +1.37% | |
| Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update | Press release | +0.00% | +0.00% | |
| Form 10-Q Cadrenal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.00% |
Keep exploring
More CVKD: analyst actions → · SEC filings → · CVKD overview →